1. Israel Stocks

  2. •

    Process industries

  3. •

    Agricultural commodities/Milling
Tikun Olam-Cannbit Pharmaceuticals Ltd.

Tikun Olam-Cannbit Pharmaceuticals Ltd.

TTASE:TKUN
125.30
ILA
+12.00
(+10.59%)
2.01BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
59.47
88.14
97.05
70.18
41.75
10.71
- -
Basic EPS, GAAP
-11,711.03
-3,749.77
-2,496.91
-796.12
-1.46
-279.89
-55.74
-90.46
-77.72
-94.96
-141.05
-47.9
-18.66
- -
Free Cash Flow per Basic Share
-2,121.72
-1,798.17
-2,148.28
-469.55
-0.93
-46.07
-83.47
-139.21
-79.7
-59.31
-6.54
-4.52
2.37
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
9,744.92
7,030.01
4,541.92
3,745.81
17.55
1.11
333.9
336.54
305.92
202.35
50.51
2.92
-15.5
-15.5
Tangible Book Value per Share
9,744.92
7,030.01
4,541.92
3,745.81
17.55
1.11
79.2
160.83
164.39
139.38
27.85
-8.62
-15.5
-15.5
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
22
37
49
44
35
9
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
-147.66
-113.94
-54.1
-64.38
-41.97
-105.36
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
14
20
52
59
30
12
- -
Net Income, GAAP
-13
-4
-3
-1
- -
-21
-11
-33
-33
-48
-89
-40
-16
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
-152.1
-88.17
-97.85
-200.97
-114.73
-174.17
- -
Working Capital
5
3
- -
-1
1
1
-8
15
20
16
-4
-13
-20
-20
LT Debt
- -
- -
- -
- -
1
4
8
7
8
8
6
5
2
2
Total Equity
11
8
5
4
- -
- -
100
136
144
117
33
-5
-21
-21
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-73.17
-43.21
-43.15
-19.21
-4.37
-13,793.49
-21.77
-27.7
-22.96
-36.24
-110.77
-184.99
- -
- -

Capital Structure

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
11
11
10
LT Borrowings
1
1
1
LT Finance Leases
3
3
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
30
33
20

Working Capital

ILS

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
6
4
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
4
3
- -
Inventories
1
1
- -
Total Current Liabilities
20
20
21
Payables & Accruals
- -
- -
- -
ST Debt
11
11
10
Deferred Revenue
- -
- -
- -

Growth Rates

ILS

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9,234.01%
18.22%
292.02%
Free Cash Flow
564.16%
-58.34%
-153.16%
Net Income, GAAP
2,174.02%
3.16%
-60.47%
Sales/Revenue/Turnover
- -
-0.22%
-73.96%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
44
2024
- -
- -
35
2025
- -
- -
9

Semi-annual Earnings Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-141.05
2024
- -
- -
-47.9
2025
- -
- -
-18.66

Semi-annual Dividends Per Share

ILS

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Avinoam Sapir
Full Time Employees
4
Sector
Process industries
Industry
Agricultural commodities/Milling
Address
Hitad 2 Tel Aviv-Yafo TA Israel 1789030
IPO Date
Mar 1, 2000
Website
tamirfishman.com
Similar Companies
Patanjali Foods Limited (NSE:PATANJALI)
Tilray Brands, Inc. (NASDAQ:TLRY)
Archer-Daniels-Midland Company (NYSE:ADM)
Corteva, Inc. (NYSE:CTVA)
Canopy Growth Corporation (NASDAQ:CGC)
Balrampur Chini Mills Ltd (NSE:BALRAMCHIN)
Business
Tikun Olam-Cannbit Pharmaceuticals Ltd is a pharmaceutical company specializing in the research, development, cultivation, production, marketing, storage, distribution, export, and sale of cannabis-based medical products. The company provides a broad portfolio of medical cannabis products targeting relief and treatment across numerous medical indications such as cancer, PTSD, epilepsy, Crohn's disease, multiple sclerosis, cerebral palsy, and chronic pain. Core offerings include proprietary cannabis strains developed through extensive genetic R&D, advanced cultivation methods yielding approximately 9 tonnes annually, and innovative dosing techniques supported by over 35 clinical and preclinical studies. Tikun Olam-Cannbit also offers patient training, counseling, and care services through its integrated ecosystem that spans from cultivation farms to direct delivery with personalized treatment regimens. The company operates primarily in Israel, with a production facility in the northern region and cultivation farms near the Dead Sea, and serves global markets including Europe, benefiting from recent EU-GMP certification that facilitates production and export of medical cannabis products internationally. Founded in 2006 and headquartered in Nof HaGalil, Israel, Tikun Olam was acquired by Cannbit Pharmaceuticals in 2019, expanding its operational and research capabilities. Recent major developments include securing EU-GMP certification in 2025 to advance international market expansion, establishing strategic partnerships such as the supply agreement with SciSparc for CBD-rich oil use in neurological treatments, and ongoing clinical trials supporting novel product innovations and formulations. The company is positioned to grow within key markets including Israel, the US, and Europe, leveraging its legacy of scientific research, robust clinical data, and integrated care approach to meet evolving medical cannabis demands worldwide. Tikun Olam-Cannbit Pharmaceuticals Ltd remains focused on sustainable growth through global production agreements and the continuous enhancement of products aimed at improving patients’ quality of life using clinically supported cannabis therapies.